Close Menu

NEW YORK –Swedish personalized cancer genomics startup Saga Diagnostics and Rostock, Germany-based SensID said on Wednesday that they have partnered to develop control reagents for cancer mutation detection.

The European collaborators will use SensID's controls with Saga's digital PCR-based Sagasafe technology, which can detect and quantify circulating tumor DNA in cancer patients at ultra-low allelic frequencies (AF).

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Dec
15
Sponsored by
UgenTec

Diverse components of the UC Davis campus have been mobilized to deploy HTP testing to provide a safe working environment and keep the pandemic under control.